1. Hasin, Y., Seldin, M. & Lusis, A. Multi-omics approaches to disease. Genome Biol. 18, 83 (2017).
2. Karczewski, K. J. & Snyder, M. P. Integrative omics for health and disease. Nat. Rev. Genet. 19, 299–310 (2018).
3. Claussnitzer, M. et al. A brief history of human disease genetics. Nature 577, 179–189 (2020).
4. Hardy, J. The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics. Science (80-. ). 297, 353–356 (2002).
5. Hardy, J. Amyloid, the presenilins and Alzheimer’s disease. Trends Neurosci. 20, 154–159 (1997).
6. Lanoiselée, H. M. et al. APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases. PLoS Med. (2017) doi:10.1371/journal.pmed.1002270.
7. Melzer, D., Pilling, L. C. & Ferrucci, L. The genetics of human ageing. Nat. Rev. Genet. 21, 88–101 (2020).
8. 2020 Alzheimer’s disease facts and figures. Alzheimer’s Dement. 16, 391–460 (2020).
9. Zissimopoulos, J., Crimmins, E. & St.Clair, P. The Value of Delaying Alzheimer’s Disease Onset. Forum Heal. Econ. Policy 18, 25–39 (2015).
10. Gatz, M. et al. Heritability for Alzheimer’s disease: The study of dementia in Swedish twins. Journals Gerontol. - Ser. A Biol. Sci. Med. Sci. 52, (1997).
11. Gatz, M. et al. Role of genes and environments for explaining Alzheimer disease. Arch. Gen. Psychiatry 63, 168–174 (2006).
12. Zhou, X., Fu, A. K. & Ip, N. Y. APOE signaling in neurodegenerative diseases: an integrative approach targeting APOE coding and noncoding variants for disease intervention. Current Opinion in Neurobiology (2021) doi:10.1016/j.conb.2021.02.001.
13. Liu, C. C., Kanekiyo, T., Xu, H. & Bu, G. Apolipoprotein e and Alzheimer disease: Risk, mechanisms and therapy. Nature Reviews Neurology vol. 9 106–118 (2013).
14. Jun, G. R. et al. Transethnic genome-wide scan identifies novel Alzheimer’s disease loci. Alzheimer’s Dement. 13, 727–738 (2017).
15. Jia, L. et al. Prediction of Alzheimer’s disease using multi-variants from a Chinese genome-wide association study. Brain 8, 99 (2020).
16. Marioni, R. E. et al. Genetic Stratification to Identify Risk Groups for Alzheimer’s Disease. J. Alzheimer’s Dis. 57, 275–283 (2017).
17. Kunkle, B. W. et al. Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nat. Genet. 51, 414–430 (2019).
18. Jansen, I. E. et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk. Nat. Genet. 51, 404–413 (2019).
19. Kunkle, B. W. et al. Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel: A Meta-analysis. JAMA Neurol. 78, 102–113 (2021).
20. Jia, L. et al. Prediction of Alzheimer’s disease using multi-variants from a Chinese genome-wide association study. Brain (2020) doi:10.1093/brain/awaa364.
21. Bellenguez, C., Küçükali, F., Jansen, I., Andrade, V. & Moreno-grau, S. New insights on the genetic etiology of Alzheimer’s and related dementia. MedRxiv 1–35 (2020).
22. Schwartzentruber, J. et al. Genome-wide meta-analysis, fine-mapping and integrative prioritization implicate new Alzheimer’s disease risk genes. Nat. Genet. 53, 392–402 (2021).
23. Wightman, D. P. et al. Largest GWAS (N=1,126,563) of Alzheimer’s Disease Implicates Microglia and Immune Cells. medRxiv 2020.11.20.20235275 (2020) doi:10.1101/2020.11.20.20235275.
24. Zhou, X. et al. Identification of genetic risk factors in the Chinese population implicates a role of immune system in Alzheimer’s disease pathogenesis. Proc. Natl. Acad. Sci. U. S. A. 115, 1697–1706 (2018).
25. Arias, J. J., Tyler, A. M., Douglas, M. P. & Phillips, K. A. Private payer coverage policies for ApoE-e4 genetic testing. Genet. Med. (2021) doi:10.1038/s41436-020-01042-4.
26. Khera, A. V. et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nature Genetics (2018) doi:10.1038/s41588-018-0183-z.
27. Torkamani, A., Wineinger, N. E. & Topol, E. J. The personal and clinical utility of polygenic risk scores. Nature Reviews Genetics (2018) doi:10.1038/s41576-018-0018-x.
28. Choi, S. W., Mak, T. S. H. & O’Reilly, P. F. Tutorial: a guide to performing polygenic risk score analyses. Nature Protocols (2020) doi:10.1038/s41596-020-0353-1.
29. Purcell, S. M. et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature (2009) doi:10.1038/nature08185.
30. Escott-Price, V. et al. Polygenic risk of Parkinson disease is correlated with disease age at onset. Ann. Neurol. (2015) doi:10.1002/ana.24335.
31. Sun, L. et al. Polygenic risk scores in cardiovascular risk prediction: A cohort study and modelling analyses. PLoS Med. (2021) doi:10.1371/JOURNAL.PMED.1003498.
32. Harrison, J. R., Mistry, S., Muskett, N., Escott-Price, V. & Brookes, K. From Polygenic Scores to Precision Medicine in Alzheimer’s Disease: A Systematic Review. J. Alzheimer’s Dis. 74, 1271–1283 (2020).
33. Escott-Price, V., Myers, A. J., Huentelman, M. & Hardy, J. Polygenic risk score analysis of pathologically confirmed Alzheimer disease. Ann. Neurol. 82, 311–314 (2017).
34. Sorbi, S. et al. Epistatic effect of APP717 mutation and apolipoprotein E genotype in familial Alzheimer’s disease. Ann. Neurol. 38, 124–7 (1995).
35. Combarros, O., Cortina-Borja, M., Smith, A. D. & Lehmann, D. J. Epistasis in sporadic Alzheimer’s disease. Neurobiol. Aging 30, 1333–49 (2009).
36. Hohman, T. J., Koran, M. E. & Thornton-Wells, T. Epistatic genetic effects among alzheimer’s candidate genes. PLoS One (2013) doi:10.1371/journal.pone.0080839.
37. Zhou, X. et al. Genetic and polygenic risk score analysis for Alzheimer’s disease in the Chinese population. Alzheimer’s Dement. (Amsterdam, Netherlands) 12, e12074 (2020).
38. Badré, A., Zhang, L., Muchero, W., Reynolds, J. C. & Pan, C. Deep neural network improves the estimation of polygenic risk scores for breast cancer. J. Hum. Genet. (2020) doi:10.1038/s10038-020-00832-7.
39. Yin, B. et al. Using the structure of genome data in the design of deep neural networks for predicting amyotrophic lateral sclerosis from genotype. in Bioinformatics (2019). doi:10.1093/bioinformatics/btz369.
40. Mueller, S. G. et al. The Alzheimer’s disease neuroimaging initiative. Neuroimaging Clinics of North America vol. 15 869–877 (2005).
41. Lee, J. H., Cheng, R., Graff-Radford, N., Foroud, T. & Mayeux, R. Analyses of the national institute on aging late-onset Alzheimer’s disease family study: Implication of additional loci. Arch. Neurol. (2008) doi:10.1001/archneur.65.11.1518.
42. Jun, G. et al. Meta-analysis confirms CR1, CLU, and PICALM as Alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch. Neurol. (2010) doi:10.1001/archneurol.2010.201.
43. Naj, A. C. et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer’s disease. Nat. Genet. (2011) doi:10.1038/ng.801.
44. Wightman, D. P. et al. Largest GWAS (N=1,126,563) of Alzheimer’s Disease Implicates Microglia and Immune Cells. medRxiv 2020.11.20.20235275 (2020) doi:10.1101/2020.11.20.20235275.
45. Schwartzentruber, J. et al. Genome-wide meta-analysis, fine-mapping, and integrative prioritization identify new Alzheimer’s disease risk genes. medRxiv 53, 392–402 (2020).
46. Jia, L. et al. Prediction of Alzheimer’s disease using multi-variants from a Chinese genome-wide association study. Brain 8, 99 (2020).
47. Tosto, G. et al. Polygenic risk scores in familial Alzheimer disease. Neurology 88, 1180–1186 (2017).
48. Escott-Price, V., Myers, A., Huentelman, M., Shoai, M. & Hardy, J. Polygenic Risk Score Analysis of Alzheimer’s Disease in Cases without APOE4 or APOE2 Alleles. J. Prev. Alzheimer’s Dis. 6, 16–19 (2019).
49. Leuzy, A., Cullen, N. C., Mattsson-Carlgren, N. & Hansson, O. Current advances in plasma and cerebrospinal fluid biomarkers in Alzheimer’s disease. Curr. Opin. Neurol. Publish Ah, 266–274 (2021).
50. Poulin, S. P., Dautoff, R., Morris, J. C., Barrett, L. F. & Dickerson, B. C. Amygdala atrophy is prominent in early Alzheimer’s disease and relates to symptom severity. Psychiatry Res. - Neuroimaging 194, 7–13 (2011).
51. Frisoni, G. B. et al. Detection of grey matter loss in mild Alzheimer’s disease with voxel based morphometry. J. Neurol. Neurosurg. Psychiatry 73, 657–664 (2002).
52. Prins, N. D. & Scheltens, P. White matter hyperintensities, cognitive impairment and dementia: An update. Nature Reviews Neurology (2015) doi:10.1038/nrneurol.2015.10.
53. Huuskonen, J., Olkkonen, V. M., Jauhiainen, M. & Ehnholm, C. The impact of phospholipid transfer protein (PLTP) on HDL metabolism. Atherosclerosis 155, 269–281 (2001).
54. Marsland, B. J. et al. CCL19 and CCL21 induce a potent proinflammatory differentiation program in licensed dendritic cells. Immunity 22, 493–505 (2005).
55. Zheng, C., Zhou, X. W. & Wang, J. Z. The dual roles of cytokines in Alzheimer’s disease: Update on interleukins, TNF-α, TGF-β and IFN-γ. Translational Neurodegeneration vol. 5 1–15 (2016).
56. Van Der Wijst, M. G. P. et al. Single-cell RNA sequencing identifies celltype-specific cis-eQTLs and co-expression QTLs. Nat. Genet. 50, 493–497 (2018).
57. Herling, M. et al. High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia. Blood 114, 4675–4686 (2009).
58. Heppner, F. L., Ransohoff, R. M. & Becher, B. Immune attack: The role of inflammation in Alzheimer disease. Nature Reviews Neuroscience (2015) doi:10.1038/nrn3880.
59. Zhavoronkov, A., Bischof, E. & Lee, K.-F. Artificial intelligence in longevity medicine. Nat. Aging 1, 5–7 (2021).
60. Porter, T. et al. A Polygenic Risk Score Derived From Episodic Memory Weighted Genetic Variants Is Associated With Cognitive Decline in Preclinical Alzheimer’s Disease. Front. Aging Neurosci. 10, 1–11 (2018).
61. Karikari, T. K. et al. Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s Disease Neuroimaging Initiative. Mol. Psychiatry (2021) doi:10.1038/s41380-020-00923-z.
62. Jia, L. et al. Prediction of Alzheimer’s disease using multi-variants from a Chinese genome-wide association study. Brain (2020) doi:10.1093/brain/awaa364.
63. Wang, K., Li, M. & Hakonarson, H. ANNOVAR: Functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. (2010) doi:10.1093/nar/gkq603.
64. Jun, G., Wing, M. K., Abecasis, G. R. & Kang, H. M. An efficient and scalable analysis framework for variant extraction and refinement from population-scale DNA sequence data. Genome Res. (2015) doi:10.1101/gr.176552.114.
65. Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: A flexible trimmer for Illumina sequence data. Bioinformatics (2014) doi:10.1093/bioinformatics/btu170.
66. Browning, S. R. & Browning, B. L. Rapid and accurate haplotype phasing and missing-data inference for whole-genome association studies by use of localized haplotype clustering. Am. J. Hum. Genet. (2007) doi:10.1086/521987.
67. Li, Y., Sidore, C., Kang, H. M., Boehnke, M. & Abecasis, G. R. Low-coverage sequencing: Implications for design of complex trait association studies. Genome Res. (2011) doi:10.1101/gr.117259.110.